Industry / innovation partners

AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.

A Licensing Deal Is Not Access. But It Decides Whether Access Is Possible.

Gene therapy is entering cardiology. Friedreich ataxia shows why rare heart disease may be the first test

Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.

Europe’s next stroke bet: can Factor XIa inhibition change prevention without raising bleeding risk?

MASH, a serious fatty liver disease, is becoming a cardiometabolic condition

Bird Flu Reached Australia. Now Preparedness Has to Deliver.

ESC Cardio-Oncology 2026: Cancer therapy is getting smarter. Cardiac protection is still playing catch-up.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
